Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission

Citation
K. Pillay et al., Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission, J INFEC DIS, 183(4), 2001, pp. 653-656
Citations number
15
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF INFECTIOUS DISEASES
ISSN journal
00221899 → ACNP
Volume
183
Issue
4
Year of publication
2001
Pages
653 - 656
Database
ISI
SICI code
0022-1899(20010215)183:4<653:SLPIIV>2.0.ZU;2-E
Abstract
The presence of both viral particles and antiviral mucosal proteins may rep resent critical determinants of perinatal human immunodeficiency virus type 1 (HIV-1) transmission. In 60 HIV-1-infected women, concentrations of the innate mucosal protein, secretory leukocyte protease inhibitor (SLPI), were lower in vaginal fluid samples from 17 women whose babies became infected than in samples from nontransmitting women (mean +/- SE, 57 +/- 11 vs. 557 +/- 177 ng/mL, respectively; P = .01). Rates of transmission among women wi th higher SLPI concentrations (>100 ng/mL) were lower than those among wome n with lower concentrations (<100 ng/mL; 8.7% vs. 40.5%, respectively; P = .01). Concentrations of other putative HIV-1-inhibitory innate immune facto rs were similar in both groups. Concentrations of vaginal HIV-1 tended to b e higher in transmitting than in nontransmitting women (407 vs. 174 virions /mL; P = .09). Increased concentrations of selected innate mucosal immune f actors, such as SLPI, seem to be associated with reduced rates of perinatal HIV-1 transmission and may contribute to natural antiretroviral defense.